TY - JOUR
T1 - The global NAFLD policy review and preparedness index
T2 - Are countries ready to address this silent public health challenge?
AU - NAFLD policy review collaborators
AU - Lazarus, Jeffrey V.
AU - Mark, Henry E.
AU - Villota-Rivas, Marcela
AU - Palayew, Adam
AU - Carrieri, Patrizia
AU - Colombo, Massimo
AU - Ekstedt, Mattias
AU - Esmat, Gamal
AU - George, Jacob
AU - Marchesini, Giulio
AU - Novak, Katja
AU - Ocama, Ponsiano
AU - Ratziu, Vlad
AU - Razavi, Homie
AU - Romero-Gómez, Manuel
AU - Silva, Marcelo
AU - Spearman, C. Wendy
AU - Tacke, Frank
AU - Tsochatzis, Emmanuel A.
AU - Yilmaz, Yusuf
AU - Younossi, Zobair M.
AU - Wong, Vincent W.S.
AU - Zelber-Sagi, Shira
AU - Cortez-Pinto, Helena
AU - Anstee, Quentin M.
AU - Rouabhia, Samir
AU - Ghazinyan, Hasmik
AU - Iskandar, Natacha Jreige
AU - Trauner, Michael
AU - Aghayeva, Gulnara
AU - Carter, Flloyd
AU - Sridharan, Kannan
AU - Al Mahtab, Mamun
AU - Francque, Sven
AU - Kodjoh, Nicolas
AU - Camacho, Ruben Muñoz
AU - Anderson, Motswedi
AU - Marques Souza de Oliveira, Claudia Pinto
AU - Mateva, Lyudmila
AU - Serme, Abdel Karim
AU - Soares Martins, Antonieta A.
AU - Swain, Mark G.
AU - Komas, Narcisse Patrice
AU - Zheng, Ming Hua
AU - Jaramillo, Patricio Lopez
AU - Murillo, Omar Alfaro
AU - Mikolasevic, Ivana
AU - Vounou, Emmelia
AU - Brůha, Radan
AU - Hamid, Saeed
N1 - Funding Information:
HEM, MV-R, and AP report receiving consulting fees from the EASL International Liver Foundation related to this work. The EASL International Liver Foundation received grants from Intercept, Bristol-Myers-Squibb Company, Genfit, and MSD to support this study. The funders played no role in the conceptualisation, design, data collection, analysis, decision to publish, or preparation of the manuscript. All other authors declare no relevant completing interests.
Funding Information:
The data collection and analysis were funded by the EASL International Liver Foundation with support from, Intercept , Bristol-Myers-Squibb Company , Genfit , and MSD . Data collection for the original European data was funded by the EASL International Liver Foundation supported by Gilead Sciences Europe Ltd. , Allergan Pharmaceutical International Ltd. , Bristol-Myers-Squibb Company , Pfizer Inc. , and Resoundant Inc .
Funding Information:
The data collection and analysis were funded by the EASL International Liver Foundation with support from, Intercept, Bristol-Myers-Squibb Company, Genfit, and MSD. Data collection for the original European data was funded by the EASL International Liver Foundation supported by Gilead Sciences Europe Ltd., Allergan Pharmaceutical International Ltd., Bristol-Myers-Squibb Company, Pfizer Inc., and Resoundant Inc.
Publisher Copyright:
© 2021 The Author(s)
PY - 2022/4
Y1 - 2022/4
N2 - Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD policies, guidelines, civil society engagement, clinical management, and epidemiologic data. A preparedness index was developed by coding questions into 6 domains (policies, guidelines, civil awareness, epidemiology and data, NAFLD detection, and NAFLD care management) and categorising the responses as high, medium, and low; a multiple correspondence analysis was then applied. Results: The highest scoring countries were India (42.7) and the United Kingdom (40.0), with 32 countries (31%) scoring zero out of 100. For 5 of the domains a minority of countries were categorised as high-level while the majority were categorised as low-level. No country had a national or sub-national strategy for NAFLD and <2% of the different strategies for related conditions included any mention of NAFLD. National NAFLD clinical guidelines were present in only 32 countries. Conclusions: Although NAFLD is a pressing public health problem, no country was found to be well prepared to address it. There is a pressing need for strategies to address NAFLD at national and global levels. Lay summary: Around a third of the countries scored a zero on the NAFLD policy preparedness index, with no country scoring over 50/100. Although NAFLD is a pressing public health problem, a comprehensive public health response is lacking in all 102 countries. Policies and strategies to address NAFLD at the national and global levels are urgently needed.
AB - Background & Aims: Non-alcoholic fatty liver disease (NAFLD) is a highly prevalent, yet largely underappreciated liver condition which is closely associated with obesity and metabolic disease. Despite affecting an estimated 1 in 4 adults globally, NAFLD is largely absent on national and global health agendas. Methods: We collected data from 102 countries, accounting for 86% of the world population, on NAFLD policies, guidelines, civil society engagement, clinical management, and epidemiologic data. A preparedness index was developed by coding questions into 6 domains (policies, guidelines, civil awareness, epidemiology and data, NAFLD detection, and NAFLD care management) and categorising the responses as high, medium, and low; a multiple correspondence analysis was then applied. Results: The highest scoring countries were India (42.7) and the United Kingdom (40.0), with 32 countries (31%) scoring zero out of 100. For 5 of the domains a minority of countries were categorised as high-level while the majority were categorised as low-level. No country had a national or sub-national strategy for NAFLD and <2% of the different strategies for related conditions included any mention of NAFLD. National NAFLD clinical guidelines were present in only 32 countries. Conclusions: Although NAFLD is a pressing public health problem, no country was found to be well prepared to address it. There is a pressing need for strategies to address NAFLD at national and global levels. Lay summary: Around a third of the countries scored a zero on the NAFLD policy preparedness index, with no country scoring over 50/100. Although NAFLD is a pressing public health problem, a comprehensive public health response is lacking in all 102 countries. Policies and strategies to address NAFLD at the national and global levels are urgently needed.
KW - Non-alcoholic fatty liver disease (NAFLD)
KW - global public health
KW - health policy
KW - liver health
KW - multiple correspondence analysis
KW - non-alcoholic steatohepatitis (NASH)
KW - policy preparedness
UR - http://www.scopus.com/inward/record.url?scp=85122443139&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2021.10.025
DO - 10.1016/j.jhep.2021.10.025
M3 - Article
C2 - 34895743
AN - SCOPUS:85122443139
SN - 0168-8278
VL - 76
SP - 771
EP - 780
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 4
ER -